title: Central IGF-I Receptors in the Brain are Instrumental to Neuroprotection by Systemically Injected IGF-I in a Rat Model for Ischemic Stroke.
abstract: Insulin-like growth factor I (IGF-I) is a neuroprotective agent in animal models of ischemic stroke. The purpose of this study was to determine whether systemically injected IGF-I exerts its neuroprotective action by binding to IGF-I receptors in the brain after crossing the blood-brain barrier, or via peripheral effects.
  
  
  
  To differentiate the central effects of IGF-I from systemic effects, ischemic stroke was induced in conscious male Wistar Kyoto rats by the injection of endothelin-1 adjacent to the middle cerebral artery in the right hemisphere, while either the IGF-I receptor antagonist JB-1 or vehicle was introduced into the right lateral ventricle.
  
  
  
  Intravenous injection of recombinant human (rh)IGF-I resulted in 50% reduction in infarct size, which was counteracted by the central administration of JB-1. Furthermore, rhIGF-I was detected in both the ischemic and nonischemic hemisphere.
  
  
  
  Systemically injected rhIGF-I passes the blood-brain barrier and protects neurons via IGF-I receptors in the brain in rats with an ischemic stroke.
authors.affiliation: Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
authors.forename: Deborah
authors.initials: D
authors.lastname: De Geyter
authors.affiliation: Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium.|Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
authors.forename: Ann
authors.initials: A
authors.lastname: De Smedt
authors.affiliation: Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
authors.forename: Wendy
authors.initials: W
authors.lastname: Stoop
authors.affiliation: Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium.|Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium.|Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands.
authors.forename: Jacques
authors.initials: J
authors.lastname: De Keyser
authors.affiliation: Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
authors.forename: Ron
authors.initials: R
authors.lastname: Kooijman
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001786:Blood Glucose; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004195:Disease Models, Animal; D004333:Drug Administration Routes; D007839:Functional Laterality; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy*; D007334:Insulin-Like Growth Factor I / Q000737:chemistry / Q000627:therapeutic use*; D008297:Male; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009842:Oligopeptides / Q000008:administration & dosage; D051381:Rats; D011921:Rats, Inbred WKY; D017526:Receptor, IGF Type 1 / Q000378:metabolism*; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D018696:Neuroprotective Agents; D009842:Oligopeptides; C411572:H 1356; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1
keywords: Blood-brain barrier; Cerebral stroke; Endothelins; Insulin-like growth factor I; Middle cerebral artery; Neuroprotection